Clinical trials: Resectable Stage II-IIIB NSCLC
Sintilimab, Lung Cancer
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
primary purpose：Observe the pathological complete response rate (PCR) of postoperative tumor tissue resection and evaluate the safety of the treatment process.
- Conditions
- Sintilimab, Lung Cancer, Anlotinib, Chemotherapy
- Trial name
- NCT05400070
- Testing
- Neoadjuvant therapy 1
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital